Form 4: Biogen CEO Christopher Viehbacher Reports Stock Transactions
SEC Form 4 Filing
Biogen's CEO, Christopher Viehbacher, reports the acquisition and disposal of company stock and restricted stock units.
Summary
- On February 7, 2025, Christopher Viehbacher, the President and CEO of Biogen Inc., reported transactions involving Biogen's common stock and restricted stock units.
- Viehbacher acquired 9,008 shares of common stock through the vesting of restricted stock units at a price of $0.
- He also disposed of 3,201 shares of common stock to cover tax obligations at a price of $141.35 per share.
- Following these transactions, Viehbacher directly owns 12,807 shares of Biogen common stock.
- Viehbacher also reports holding 46,360 restricted stock units granted on February 6, 2025, vesting in three equal yearly installments beginning February 6, 2026.
- Additionally, he holds 18,017 restricted stock units granted on February 7, 2024, vesting in three equal annual installments commencing one year after the grant date.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock transactions by an executive. It doesn't inherently indicate positive or negative sentiment, as the transactions are related to compensation and tax obligations.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to gauge management's sentiment and confidence in the company's prospects.
Stakeholder Impact
- The transactions may have a minor impact on shareholders by slightly increasing the number of shares outstanding.
- The disposal of shares to cover tax obligations is a normal part of executive compensation and shouldn't significantly impact stakeholders.
Key Dates
| Date | Description |
|---|---|
| 02/07/2024 | Grant date of restricted stock units vesting in three equal annual installments commencing one year after the grant date. |
| 02/06/2025 | Grant date of restricted stock units vesting in three equal yearly installments beginning on the first anniversary of the grant date. |
| 02/06/2025 | Date of earliest transaction reported. |
| 02/07/2025 | Date of stock acquisition and disposal. |
| 02/10/2025 | Date of signature on the Form 4 filing. |
| 02/06/2026 | First vesting date for restricted stock units granted on February 6, 2025. |
| 02/07/2027 | Expiration date for restricted stock units. |
| 02/06/2028 | Expiration date for restricted stock units. |
Keywords
Form 4, BIIB, Biogen, Viehbacher, Christopher Viehbacher, Stock, Restricted Stock Units, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.